Prodotti competitors / Area Oncology
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Article
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T Li, MD, Prof Funda Meric-Bernstam, MD, Aditya Bardia, MD, Yoichi Naito, MD, Prof Salvatore Siena, MD, Philippe Aftimos, MD, et al.
was published on May 03, 2024 in The Lance Oncology
The DESTINY-PanTumor01 study showed clinically meaningful activity of trastuzumab deruxtecan in various solid tumours harbouring prespecified activating HER2 mutations, including patients with no detectable HER2 protein expression. In heavily pretreated patients with few treatment options, trastuzumab deruxtecan showed encouraging anti-tumour activity and durable responses across multiple tumour types with activating HER2 mutations.
Grazie per il tuo feedback!